Zoetis Inc. (NYSE:ZTS) Shares Sold by Pinion Investment Advisors LLC

Pinion Investment Advisors LLC decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 8.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,352 shares of the company’s stock after selling 228 shares during the quarter. Pinion Investment Advisors LLC’s holdings in Zoetis were worth $408,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Private Wealth Management Group LLC acquired a new position in shares of Zoetis in the 4th quarter worth $33,000. Webster Bank N. A. boosted its position in shares of Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after purchasing an additional 82 shares during the period. Neo Ivy Capital Management purchased a new position in Zoetis in the 4th quarter worth about $40,000. LRI Investments LLC acquired a new stake in Zoetis during the 1st quarter worth about $43,000. Finally, Ables Iannone Moore & Associates Inc. purchased a new stake in Zoetis during the fourth quarter valued at about $51,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $191.09 on Friday. The firm has a market cap of $86.57 billion, a P/E ratio of 36.82, a PEG ratio of 2.92 and a beta of 0.88. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The stock’s 50-day moving average is $182.85 and its two-hundred day moving average is $174.32.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.41 earnings per share. Analysts predict that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on ZTS shares. Stifel Nicolaus reissued a “buy” rating and issued a $200.00 target price on shares of Zoetis in a research report on Tuesday, August 27th. Piper Sandler lifted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. BTIG Research boosted their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Zoetis has a consensus rating of “Buy” and an average price target of $217.11.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.